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ABSTRACT
Activating Transcription Factor 3 (ATF3), a member
of the ATF/CREB family, is induced rapidly by
various stresses. Its induction mechanism and
role in response to changes in cellular redox
status, however, have not been elucidated. Here,
we found that NF-E2-related factor 2 (Nrf2), a tran-
scription factor known to bind to antioxidant
response element (ARE) in promoters, transcrip-
tionally upregulated ATF3 expression in astrocytes.
Treatment with Nrf2 activators and oxidants
provoked ATF3 induction in astrocytes, whereas its
expression was reduced in Nrf2-depleted cells. We
further demonstrated that the consensus ARE in the
ATF3 promoter is critical for Nrf2-mediation by
promoter analyses using an ATF3 promoter-driven
luciferase construct and a chromatin immunopre-
cipitation assay. In addition, we found that Nrf2-
dependent ATF3 induction contributed to the
antioxidative and cytoprotective functions of Nrf2
in astrocytes. Taken together, our findings suggest
that ATF3 is a new target for Nrf2 and has a
cytoprotective function in astrocytes.
INTRODUCTION
Aerobic life is constantly challenged by oxidative stress.
To cope with this stress, biological systems have devised
defense mechanisms. The perturbation of this protective
regulation causes the accumulation of reactive oxygen
species (ROS), which contribute to the pathogenesis of
various diseases including neurological and neuro-
degenerative disorders. Nrf2, a member of the
Cap‘n’Collar subfamily of basic-region leucine zipper
(bZIP) transcription factor family, plays a pivotal role in
the defense system against oxidative stress. Nrf2 is
normally degraded in the cytoplasm when it interacts
with Keap1. However, oxidative stress leads to the disso-
ciation of Nrf2 from Keap1, resulting in the accumulation
of Nrf2 in the nucleus. Stabilized Nrf2 induces the expres-
sion of several cytoprotective and antioxidant enzymes
by binding to antioxidant response element (ARE) in
their promoter regions. In the nervous systems, Nrf2 is
predominantly active in astrocytes (1). Preferential activa-
tion of Nrf2 in astrocytes confers neuronal protec-
tion against oxidative stress (2,3) and prevents the
pathogenesis of familial amyotrophic lateral sclerosis
and Parkinson’s disease (4,5).
ATF3, a bZIP-containing ATF/CREB family transcrip-
tion factor, is a stress-responsive gene. The expression of
ATF3 is rapidly induced upon exposure to numerous
stresses including oxidative stress, while it remains at
low level in normal conditions (6). It has been previously
reported that JNK/SAPK, ERK/MAPK, and p38 signal-
ing pathways are involved in the mechanism of ATF3
induction (7,8), suggesting that there are many upstream
regulatory molecules for ATF3 induction. Since most of
ATF3 inductions are linked to an increase in the expres-
sion of transcripts, the information on the regulation of
the ATF3 promoter would provide insight for understand-
ing the mechanisms of ATF3 expression. However, rela-
tively little has been described in the context of the
transcriptional control of the ATF3 promoter.
Here, we found that Nrf2 up-regulates ATF3 expression
in astrocytes and Nrf2-binding site is located in the ATF3
promoter. Furthermore, we revealed that Nrf2-mediated
ATF3 induction in astrocytes contributed to the
cytoprotective function of Nrf2 against oxidative insults.
MATERIALS AND METHODS
Cell culture and chemicals
Human primary brain astrocytes were purchased from the
Applied Cell Biology Research Institute (Kirkland, WA,
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10% FBS (Invitrogen, Carlsbad, CA, USA). Mouse
primary cerebral astrocytes were puriﬁed from neonatal
ICR mice according to standard procedure (9). Mouse
embryonic ﬁbroblasts (MEFs) were isolated from
Nrf2
+/+ and Nrf2
 /  mice (which were generously
provided by Dr. Jeﬀrey A. Johnson, University of
Wisconsin, WI, USA). Tert-butylhydroquinone (tBHQ)
and butylated hydroxyanisole (BHA) were purchased
from Fisher Scientiﬁc (Fairlawn, NY, USA) and sodium
arsenite (AS) and phenazine methosulfate (PMS) were
purchased from Sigma (St Louis, MO, USA).
Western blot analysis
Equal amounts of proteins were separated on 11% SDS–
PAGE gels, transferred onto nitrocellulose membranes,
and incubated with antibodies speciﬁc for Nrf2, ATF3,
HO1 and b-actin (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). The expressions of ATF3 and b-actin
were analyzed quantitatively using an image analysis
software (NIH-Image J).
Immunocytochemistry
Cells were washed with phosphate buﬀered saline (PBS),
ﬁxed with 3.7% formaldehyde, and permeabilized with
0.5% Triton X-100 in PBS. After blocking with 1%
blocking reagent (Roche) for 1h, cells were incubated
with the anti-ATF3 antibody overnight at 4 C, followed
by incubation with an FITC-conjugated secondary
antibody. Immunocytochemical analysis using the anti-
phospho-histone H2A.X antibody (ser139) (Millipore,
Billeria, MA, USA) was performed according to the man-
ufacturer’s instructions. Human astrocytes were ﬁxed with
5% acetic acid in ethanol for 5min. After blocking
with 3% BSA for 30min, cells were incubated with
anti-phospho-histone H2A.X antibody for 1h, followed
by incubation with an FITC-conjugated secondary
antibody. After counterstaining with 2mg/ml of 40,
60-diamidine-2-phenylindole dihydrochloride (DAPI)
(Roche), images were acquired using an Axiovert M200
microscope (Zeiss, Oberkochen, Germany).
RT–PCR and quantitative real-time PCR
Total RNA was isolated from astrocytes using the TRIzol
reagent (Molecular Research Center, Cincinati, OH,
USA). cDNAs were synthesized using an oligo-(dT)
primer and MMLV reverse transcriptase (Promega,
Madison, WI, USA) and were used in subsequent PCR
reaction using speciﬁc primer sets for human ATF3 (50-AT
GATGCTTCAACACCCAGG-30 and 50-TTTCGGCAC
TTTGCAGCTG-30), human Nrf2 (50-AAACCAGTGG
ATCTGCCAAC-30 and 50-GACCGGGAATATCAGGA
ACA-30) (10), human HO1 (50-GCTACCTGGGTGACC
TGTCT-30 and 50-GGGCAGAATCTTGCACTTTG-30),
human Sulﬁredoxin1 (50-CAAGGTGCAGAGCCTCGT
GG-30 and 50-AGCTGGTGAGAGGGGTGCCC-30),
human NQO1 (50-CATTCTGAAAGGCTGGTTTG-30
and 50-GGCTGCTTGGAGCAAAATAC-30), and
human b-actin (50-GACTACCTCATGAAGATC-30 and
50-GATCCACATCTGCTGGAA-30). PCR products
were resolved on 1.5% agarose gels and visualized by
ethidium bromide staining. Quantitative real-time PCR
was carried out using commercially available SYBR
green-based detection reagents (Roche, Branchburg, NJ,
USA) and a Light Cycler apparatus (Roche).
siRNA transfection
siRNA duplexes targeting human Nrf2 (siNrf2, 50-AAGA
GUAUGAGCUGGAAAAAC-30) (11), human ATF3
(siATF3#1, 50-UGAAGAAGAUGAAAGGAAA-30,
siATF3#2, 50-GAAACAAGAAGAAGGAGAA-30), and
GFP (siGFP, 50-GGCUACGTCCAGGAGCGCA-30)
were synthesized by Dharmacon (Lafayette, CO, USA)
or Samchully Pharm (Seoul, Korea). siRNAs were
transfected using Oligofectamine (Invitrogen).
Plasmid constructs
ATF3 promoter regions were ampliﬁed from human
genomic DNA by PCR using primer sets corresponding
to  3646 (50-CGGGGTACCACCACTACTGAGGGCT
GACTGG-30),  3150 (50-CGGGGTACCACCACTACT
GAGGGCTGACTGG-30), 1250 (50-CGGGGTACCAG
GTCTCAGCTCGAATCTCGG-30) and +3 (50-CCCAA
GCTTACTGTGGCTTGGAGAGCGTTG-30) positions.
PCR products were cloned into the pGL3-Basic vector.
For construction of pATF3-ARE1-SV40 and pATF3-
ARE2-SV40, fragments of approximately 200bps that
encompassed the putative ARE of the ATF3 promoter
were ampliﬁed using the following primers: for pATF3-
ARE1-luc, 50-CGGGGTACCGCCACATCCTCAGAGA
AATGTCAC-30 (forward) and 50-GGAAGATCTATTG
TCAGGAAACAGGGGCAG-30 (reverse); for pATF3-
ARE2-luc, 50-CGGGGTACCTAGATTTGGTTGCCAC
GAGTGG-30 (forward) and 50-GGAAGATCTGCAGA
GACTTGAAGATTGCTGAGG-30 (reverse). These
PCR products were cloned into the pGL3-Promoter
vector upstream of the SV40 promoter. Site-directed
mutagenesis was performed by over-lapping PCR using
the following primers: 50-AAATAACTTACTTA
AGGGTACACATAATCTAAGTGCTGAATC-30, and
reverse-complement primers (the mutated sequences were
underlined). Mouse wild-type Nrf2, dominant-negative
Nrf2 (Nrf2-DN, amino acids 296–581), and mouse
Keap1 were ampliﬁed and cloned into the pCS2+ expres-
sion vectors.
Luciferase reporter assay
HeLa cells and human astrocytes were transfected
using Lipofectamine Plus (Invitrogen). All cells were
cotransfected with the b-galactosidase expression vector
(pSV- b-galactosidase). Luciferase activity was measured
using the Luciferase assay kit (Promega) and
b-galactosidase activity was measured using
O-nitrophenyl b-galactopyranoside.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) was carried out
using the ChIP kit (Upstate Biotechnology, Lake Placid,
NY, USA). ARE of the ATF3 promoter was ampliﬁed by
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50-TACCACTACTGAGGGCTGACTGG-30, and 50-CA
TTGTCAGGAAACAGGGGC-30; for 2nd PCR of
ARE1, 50-GTGCCACATCCTCAGAGAAATG-30, and
50-CACAGTAGGCACCAAAGTGTGG-30; for PCR of
ARE2, 50-TAGATTTGGTTGCCACGAGTGG-30 and
50-GCAGAGACTTGAAGATTGCTGAGG-30. Primer
pairs corresponding to the ARE of the NQO1 promoter
were used as a positive control (12).
ROS measurement and glutathione assay
To assess the generation of ROS, human primary
astrocytes were incubated with 5mM2 0,70-dichloro-
dihydroﬂuorescein diacetate (DCFH-DA, Sigma) for
30min at 37 C. Astrocytes were analyzed on a FACScan
ﬂow cytometer (Becton Dickinson, Bedford, MA, USA)
and dichloroﬂuorescein (DCF) ﬂuorescence was derived
using the CellQuest software. The Glutathione assay
kit (Cayman Chemical, Ann Arbor, MI, USA) was used
to measure total glutathione levels. Total glutathione
[reduced glutathione (GSH)+oxidized glutathione
(GSSG)] levels were measured at 405nm, according to
the manufacturer’s instructions.
Cell viability assay
Human astrocytes were treated with oxidants. After 4h,
we examined the cellular reduction of 4-[3-(4-iodophenyl)-
2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate
(WST-1) to formazan using the EZ-Cytox Enhanced cell
viability assay kit (ITSBIO, Seoul, Korea). Cells were
incubated in a culture medium containing 10% WST-1
for 1h and the absorbance was measured at 450nm.
TdT-mediated dUTP nick and labeling assay
To detect apoptotic cells, TdT-mediated dUTP nick and
labeling (TUNEL) assay was performed using an in situ
cell detection kit according to the manufacturer’s
instructions (Roche). After ﬁxation and permeabilization,
human astrocytes were incubated with TUNEL reaction
mixtures for 1h. After counterstaining with DAPI,
apoptotic cells were observed using an Axiovert M200
microscope (Zeiss). The percentage of apoptotic cells
was calculated as the number of TUNEL-positive
apoptotic nuclei divided by the total number of nuclei
stained with DAPI.
Single-cell gel electrophoresis assay
Dissociated cells were mixed with low-melting agarose,
dropped onto a glass slide, and dried. The slide was placed
inlysisbuﬀerfor2handelectrophoresedat12Vfor20min.
The slides were stained with 2mg/ml ethidium bromide.
The DNA was then visualized using a ﬂuorescence micro-
scope (Leica CTR5000, Cambridge, UK). The DNA
damage in about 35 cells were analyzed using the Comet
Assay w program (Perceptive Instruments, Suﬀolk, UK).
Statistical analyses
All data are presented as mean±standard error of
the mean (SEM) of three independent experiments.
Signiﬁcance of diﬀerences was evaluated by unpaired
Student’s t-test.
NSP>0.05, *P<0.05, **P<0.01.
RESULTS
Nrf2 activators and oxidants induced ATF3 expression
To evaluate the role of Nrf2 in the regulation of ATF3
expression, we treated human and mouse primary
astrocytes with the Nrf2 activators, tBHQ and BHA.
Within the indicated concentration range, no apparent
cytotoxicity was observed (data not shown).
Immunoblotting results showed that tBHQ and BHA
provoked a dose-dependent induction of ATF3 as well
as heme oxygenase 1 (HO1) which is an Nrf2-target
protein (Figure 1A). This result was conﬁrmed by
immunocytochemical analysis, which showed that the
induced ATF3 was mainly localized in the nuclei of
tBHQ-treated human astrocytes (Figure 1B). In contrast,
unstimulated cells exhibited background staining.
Moreover, RT–PCR and the quantitative real-time PCR
analyses revealed that both tBHQ and BHA increased
ATF3 mRNA levels signiﬁcantly in human astrocytes
(Figure 1C and D), indicating that the induction of
ATF3 was caused by the upregulation of transcription.
To further conﬁrm that Nrf2 participated in tBHQ-
induced ATF3 expression, we used siRNA targeting
Nrf2 (siNrf2). RT–PCR analysis showed that transfection
of human astrocytes with siNrf2 reduced the levels of Nrf2
mRNA expression (Figure 2A). As shown in Figure 2B,
the depletion of Nrf2 in human astrocytes resulted in the
reduction of ATF3 and HO1 induction. Additionally,
when MEFs isolated from Nrf2
+/+ and Nrf2
 /  mice
were cultured in the presence tBHQ, ATF3 and HO1
induction were considerably reduced in Nrf2-deﬁcient
MEFs (Figure 2C).These results suggest that Nrf2 plays
an essential role in ATF3 induction after treatment with
tBHQ.
It is well known that oxidants induce the expression of
Nrf2 target genes through the stabilization of Nrf2. To
determine whether ATF3 was regulated by oxidants via
Nrf2, human astrocytes were treated with the oxidants,
sodium arsenite (AS) and phenazine methosulfate (PMS)
which generate ROS inside cells. Figure 3A shows that
both agents upregulated ATF3 and HO1 inductions in
human astrocytes. Next, we determined whether Nrf2
was critical for oxidant-induced ATF3 expression. The
depletion of Nrf2 in astrocytes reduced ATF3 and HO1
expression induced by treatment with AS or PMS (Figure
3B). Similarly, ATF3 expression was not induced by
oxidants in Nrf2
 /  MEFs (Figure 3C). The reduction
of ATF3 induction in siNrf2-transfected astrocytes
(Figure 3B) was less drastic than that observed in
Nrf2
 /  MEFs (Figure 3C). We suggest that, because
transfection of human astrocytes with siNrf2 did not
fully abolish the expression of Nrf2 mRNA, the reduction
of ATF3 induction may be insuﬃcient. Moreover, it is
possible that ATF3 induction by oxidant treatment will
be regulated by several pathways including the Nrf2/
Keap1 pathway. Nevertheless, our ﬁndings showed that
50 Nucleic AcidsResearch, 2010,Vol. 38,No. 1Nrf2 was one of the major pathways for the transcription
of the ATF3 gene.
Identiﬁcation of ARE in the ATF3 promoter
Nrf2 binds to ARE in promoter regions for the
transcriptional activation of target genes. To determine
whether the ATF3 promoter contains an ARE or not,
we analyzed about 5-kb upstream region of the human
ATF3 promoter using MOTIF search software.
Thereafter, we found two potential ARE sites, termed
ARE1 and ARE2, which were located from  3541
to  3533 and from  2975 to  2967, respectively
(Figure 4A). ARE1 exhibited perfect match with the
consensus ARE sequence, while ARE2 contained two mis-
matched bases.
To verify whether these two putative ARE sites were
functional for Nrf2, the ATF3 promoter encompassing
both ARE sites was cloned into the luciferase reporter
vector (pATF3-3.6k-luc). Luciferase activity in tBHQ-
treated human astrocytes was almost twice as high as
that measured in non-treated cells (Figure 4B). In
addition, luciferase activity was also increased in propor-
tion to increasing doses of exogenous Nrf2 (Figure 4C),
whereas Nrf2-DN lacking a transactivating domain
strongly suppressed the luciferase activity that was
increased by the overexpression of Nrf2 (Figure 4D).
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Figure 1. Nrf2 activators induce ATF3 expression in astrocytes. (A) Human primary astrocytes were treated with the indicated concentrations of
tBHQ or BHA for 24 h, and mouse primary astrocytes were treated with the indicated concentrations of tBHQ for 24h. Proteins were subjected to
Western blot analysis. The bottom bar graph shows the quantitative analysis of ATF3 expression which was normalized to b-actin expression levels
(ATF3/b-actin). The value obtained for the DMSO-treated sample was set as 100%. Data are means±SEM of three independent experiments
(*P<0.05, **P<0.01 compared with the DMSO-treated sample). (B) Human astrocytes were treated with 50mM tBHQ for 18h and immunocyto-
chemistry was then performed using the anti-ATF3 antibody. ATF3 staining was concentrated in nuclei after treatment with tBHQ (arrows).
Magniﬁcation: X400 (C) Human primary astrocytes were treated with the indicated concentrations of tBHQ or BHA for 24h. The expression
levels of ATF3 were assessed by RT–PCR. (D) Human primary astrocytes were treated with the indicated concentrations of tBHQ (left panel) or
BHA (right panel) for 24h. The expression levels of ATF3 and  -actin were assessed by quantitative real time PCR. The expression levels of ATF3
transcripts were normalized to  -actin mRNA levels. The value obtained for the DMSO-treated sample was set as 100%. Data are means±SEM of
three independent experiments (*P<0.05, **P<0.01 compared with the DMSO-treated sample).
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the cytoplasm. Consequently, the overexpression of
Keap1 almost completely repressed the transcriptional
activity increased by the overexpression of Nrf2
(Figure 4E). These results indicate that the ATF3
promoter contains Nrf2-responsive element(s).
Next, we investigated whether the two ARE sites of the
ATF3 promoter were important for Nrf2-mediated activa-
tion. Figure 5A shows that the overexpression of Nrf2
failed to induce the increase in transcriptional activity
of pATF3-1.3k-luc construct lacking both ARE sites
and pATF3-3.1k-luc construct containing only ARE2,
whereas Nrf2 increased the transcriptional activity of
pATF3-3.6k-luc construct containing both ARE sites, sug-
gesting that ARE1 may be important for Nrf2 mediation.
The mutated ARE1 markedly reduced the Nrf2-mediated
activation of the ATF3 promoter (Figure 5B). In addition,
we showed that tBHQ treatment did not increase luciferase
activity in human astrocytes transfected with mutant type
ATF3 promoter (pATF3-3.6k-luc-mut) (Figure 5C). These
results suggest that ARE1 was essential for the Nrf2-
dependent transcriptional activation of the ATF3 gene.
This ﬁnding was further conﬁrmed in experiments using
a luciferase-construct containing either ARE1 or ARE2
(pATF3-ARE1-luc or pATF3-ARE2-luc, respectively).
The pATF3-ARE1-luc construct containing only ARE1
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Figure 2. tBHQ-induced ATF3 expression is dependent on Nrf2. (A) Human astrocytes transfected with 75nM siGFP or siNrf2 were treated with
100mM tBHQ for 24h. The expression levels of Nrf2 were assessed by RT–PCR. The bottom bar graph shows the quantitative analysis of Nrf2
expression which was normalized to b-actin expression levels (Nrf2/b-actin). The value obtained for the siGFP-transfected and DMSO-treated sample
was set as 100%. Data are mean±SEM of three independent experiments (*P<0.05). (B) Human astrocytes transfected with 75nM siGFP or
siNrf2 were treated with 100mM tBHQ. After 24h incubation, Western blot was performed. The bottom bar graph shows the quantitative analysis of
ATF3 levels which were normalized to b-actin expression levels (ATF3/b-actin). The value obtained for the siGFP-transfected and DMSO-treated
sample was set as 100%. Data are mean±SEM of three independent experiments (*P<0.05). (C) MEFs isolated from Nrf2
+/+ and Nrf2
 /  mice
were treated with 20mM tBHQ for 24h. Proteins were subjected to western blot analysis. The bottom bar graph shows the quantitative analysis of
ATF3 levels which were normalized to b-actin expression levels (ATF3/b-actin). The value obtained for the DMSO-treated MEFs isolated from
Nrf2
+/+ was set as 100%. Data are mean±SEM of three independent experiments (*P<0.05).
52 Nucleic AcidsResearch, 2010,Vol. 38,No. 1exhibited the Nrf2-mediated increase in luciferase activity,
whereas the pATF3-ARE2-luc construct containing only
ARE2 did not (Figure 5D). In addition, the site-speciﬁc
mutation of the ARE1 sequence in the pATF3-ARE1-luc
construct (pATF3-ARE1-luc-mut) completely abolished
the Nrf2-mediated increase in luciferase activity
(Figure 5D). Finally, we evaluated whether Nrf2 was
able to bind ARE1 in vivo. ChIP analysis revealed that
tBHQ treatment increased Nrf2 binding to ARE1 of the
ATF3 promoters as well as ARE of the NAD(P)H: quinine
oxidoreductase (NQO1) promoter which was used as a
positive control (Figure 5E). These results suggest that
Nrf2 binds to ARE1 located in the ATF3 promoter,
thereby inducing ATF3 expression.
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functions of Nrf2 in astrocytes
To assess the importance of ATF3 induction in astrocytes,
we used two siRNAs targeting ATF3 (siATF3#1 and
siATF3#2) for the knockdown of tBHQ-induced ATF3
expression (Figure 6A). It was previously reported that
Nrf2 has an antioxidative function via the modulation of
cellular ROS levels (13). Therefore, we assessed whether
the Nrf2-dependent induction of ATF3 aﬀected cellular
ROS levels employing 20,70-dichlorodihydroﬂuorescein
diacetate (DCFH-DA) which is sensitive to oxidation by
cellular ROS. Figure 6B shows that tBHQ decreased ROS
levels in astrocytes. However, the tBHQ-mediated reduc-
tion of cellular ROS levels was decreased in ATF3-
depleted astrocytes, which implies that ATF3 may be
required for the antioxidative functions of Nrf2.
Furthermore, we examined the eﬀect of ATF3 induction
on the expression of Nrf2 target genes because ATF3
could exert its antioxidative eﬀect via the transcriptional
modulation of the expression of Nrf2 target genes.
However, the absence of ATF3 did not aﬀect the
mRNA expression of Nrf2 and Nrf2 target genes
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1 (SRXN1), and the detoxifying enzyme NQO1
(Figure 6C). Additionally, the immunocytochemical
analysis using anti-Nrf2 antibody showed that the deple-
tion of ATF3 did not aﬀect the immunoreactivity for
Nrf2 which was stabilized by treatment with tBHQ
(Supplementary Figure S1). These ﬁndings suggest that
ATF3 contributed to the antioxidative function of Nrf2
in astrocytes although ATF3 did not modulate the tran-
scription of Nrf2 and Nrf2-target genes.
Next, we speculated that ATF3 might aﬀect cellular
viability against oxidative stress. To address this, we
used siATF3 to silence the expression of ATF3 induced
by treatment with AS and PMS. WST assay was
performed to examine cytotoxicity after treatment with
AS or PMS for 24h. As shown in Figure 7A, the
absorbance was decreased in ATF3-deﬁcient astrocytes
treated with oxidants, which implies that oxidant-
induced cytotoxicity was increased by the knockdown of
ATF3. To examine apoptosis, we performed a TUNEL
assay which detects DNA fragmentation resulting from
apoptosis. The number of apoptotic cells generated by
treatment with oxidants was increased in ATF3-depleted
cells (Figure 7B and Supplementary Figure S2). Next, we
determined the eﬀect of ATF3 on DNA damage by per-
forming a single-cell gel electrophoresis assay to visualize
single- and double- strand DNA breaks. As illustrated
in Figure 7C, DNA damage was enhanced in ATF3-
depleted cells. This result was conﬁrmed by the
immunocytochemical analysis using the anti-phospho
histone H2A.X antibody. Phosphorylation of histone
H2A.X is an indication of the early DNA damage
response (14). We found that the number of foci generated
by the treatment with oxidants was increased in ATF3-
depleted cells (Figure 7D and Supplementary Figure S3).
All together, these results demonstrated that the knock-
down of ATF3 enhanced DNA damages under oxidative
stress conditions in human astrocytes.
GSH is the most abundant antioxidant. It protects cells
by scavenging ROS in stress conditions. Next, we asked
whether ATF3 was able to regulate the amount of GSH in
response to oxidants. The levels of GSH increased after
AS and PMS treatments (Figure 7E), suggesting that the
upregulation of GSH has a counter-eﬀect on oxidant-
induced damage. However, the depletion of ATF3
reduced the upregulation of GSH, which implies that
ATF3 is required for the generation of intracellular
GSH. Therefore, these data suggest that ATF3 induction
in astrocytes may contribute to the cytoprotective function
of Nrf2 against oxidative insults by modulating GSH
levels. The experiments depicted in Figure 7 were
performed using non-transfected control cells, in which
the values were not diﬀerent from those observed in
siGFP-transfected control cells (data not shown).
DISCUSSION
Cellular responses to oxidative stress are critical for the
maintenance of homeostasis. Nrf2 is rapidly activated by
oxidative reagents and ATF3 is induced by a variety of
stresses including ROS. Although Nrf2 and ATF3 are sim-
ilarly reactive against the oxidative stress, there is no direct
evidence of Nrf2-dependent ATF3 induction. Here, we
reported that ATF3 expression in astrocytes is
upregulated by the binding of Nrf2 to ARE of the ATF3
promoter and may contribute to the antioxidative activity
of Nrf2.
Two classical Nrf2 activators, tBHQ and BHA,
upregulated the ATF3 expression in astrocytes (Figure
1). However, tBHQ did not aﬀect ATF3 expression in
other type of brain cells including human brain
endothelial cells or mouse primary neuronal cells (data
not shown), which suggests the presence of astrocyte-
speciﬁc mechanism for the Nrf2-mediated induction of
ATF3 expression. Several studies showed that Nrf2
activity is higher in astrocytes than in neurons (1–3). For
instance, ARE-responsive genes NQO1 and GST are more
abundant and eﬀective in astrocytes than in neurons.
Similar to what was observed for NQO1 and GST,
ATF3 induction by tBHQ in astrocytes seemed to be
due to the strong Nrf2 activity. Moreover, we showed
that ATF3 induction in astrocytes contributes to the
cytoprotective function of Nrf2 (Figure 7). Our ﬁndings
are inconsistent with a previous study showing that ATF3
forms, a heterodimer with Nrf2 at the ARE, are present in
the promoter regions of Nrf2 target genes and represses
the function of Nrf2 to induce phase 2 enzymes in epithe-
lial cells (15). In its system, however, ATF3 was expressed
highly under normal conditions, whereas, in general, the
expression of ATF3 is rarely detected in unstimulated
conditions. Therefore, we suggest that the diﬀerences in
the characteristics of cells may determine the function of
ATF3. In support of this suggestion, both protective and
proapoptotic eﬀects of ATF3 in stressful conditions have
been reported (16–20). In particular, a recent report
showed that the molecular properties of speciﬁc cells
determine the role of ATF3 as an oncogene or as a
tumor suppressor (21). Although ATF3 has various
functions, our ﬁndings demonstrated that, in astrocytes,
Nrf2 mediated the upregulation of ATF3 and that the
synergistic action of the Nrf2-ATF3 complex promoted
the protective eﬀect of astrocytes.
In the nervous system, ATF3 is a marker of cellular
stress. Focal cerebral ischemia induces the biphasic expres-
sion of ATF3 (22) and sciatic nerve injury leads to the
upregulation of ATF3 in glial cells (23). Furthermore,
evidence suggests that ATF3 induction in the brain is a
survival response to physiological dysfunctions. For
instance, ATF3 expression rescues damaged cells in the
nervous system (19) and promotes the regeneration of
injured dorsal root ganglion peripheral neurons (20).
The mechanism that underlies the protective capacity of
ATF3 in the nervous systems, however, remains unclear.
We propose that ATF3 provides a protective function to
astrocytes under pathological conditions by modulating
the redox status and glutathione levels. However, as we
did not fully establish how ATF3 modulated redox status
and glutathione levels in astrocytes, experiments aimed at
elucidating the action of ATF3 target genes or the binding
partners of ATF3 may be helpful for understanding the
role of ATF3 in astrocytes.
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Figure 7. ATF3 contributes to protective activity of Nrf2 in astrocytes. (A) Human astrocytes were transfected with 50nM siGFP, siATF3#1 or
siATF3#2 and were then treated with 7.5mM AS or 7.5mM PMS for 24h. WST assay was performed to examine cytotoxicity. The absorbance
observed for the siGFP-transfected and DMSO-treated sample was set as 100%. Data are means±SEM of three independent experiments
(*P<0.05). (B) Human astrocytes were transfected with 50nM siGFP, siATF3#1 or siATF3#2 and were then treated with 7.5mM AS or 7.5mM
PMS for 24h. TUNEL assay was performed to examine the apoptosis induced by oxidants. The proportion of apoptotic cells was calculated as the
number of TUNEL-positive apoptotic nuclei divided by the total number of nuclei stained with DAPI. Data are mean±SEM of three independent
experiments (*P<0.05). (C) Human astrocytes were transfected with 50nM siGFP, siATF3#1 or siATF3#2 and were then treated with 7.5mMA S
for 24h. A single-cell gel electrophoresis assay was performed to assess DNA damage in individual cells. The more damaged and broken pieces of
DNA were shown in ATF3-depleted cells (upper panel). We analyzed and calculated the DNA damage in  35 cells (bottom panel) as described in
Materials and Methods section. The value for the siGFP-transfected sample was set as 100%. Data are means±SEM of three independent
experiments (*P<0.05 compared with the siGFP-transfected sample). (D) Human astrocytes were transfected with 50nM siGFP, siATF3#1 or
siATF3#2 and were then treated with 7.5mM AS or 7.5mM PMS for 24h. To examine DNA damages, immunocytochemical analysis was performed
using the anti-phospho-histone H2A.X antibody. The number of phospho-histone H2A.X-positive foci was divided by the total number of nuclei
stained with DAPI. Data are mean±SEM of three independent experiments (*P<0.05). (E) Human astrocytes were transfected with 50nM siGFP,
siATF3#1 or siATF3#2 and were then treated with 7.5mM AS or 7.5mM PMS for 24h. Total intracellular glutathione was quantiﬁed by measuring
the levels of GSH and GSSG, which were normalized to the amounts of total proteins. The amount of GSH+GSSG/the amount of protein in the
siGFP-transfected and DMSO-treated sample (20.52nmol/mg) was set as 100%. Data are mean±SEM of three independent experiments
(*P<0.05).
58 Nucleic AcidsResearch, 2010,Vol. 38,No. 1In conclusion, we showed that ATF3 was a new
member of the Nrf2/ARE regulated gene family and
forms the part of the cytoprotective system in astrocytes.
Therefore, we suggest that the synergistic activation of
Nrf2 and ATF3 in astrocytes may provide a new interven-
tion against nervous diseases caused by oxidative stress.
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